Diana Elsa Flores-Alvarado

Diana Elsa Flores-Alvarado

Auto-generated profile, based on publicly available information

Diana Elsa Flores-Alvarado

Rheumatology Service Hospital Universitario “Dr. Jose E. Gonzalez”, Universidad Autonoma de Nuevo Leon Monterrey Mexico

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
DGDionicio A. Galarza-Delgado
Dionicio A. Galarza-Delgado
JLJosé Ramón Azpiri López
José Ramón Azpiri López
ICIris J. Colunga-Pedraza
Iris J. Colunga-Pedraza
NGNatalia Guajardo-Jauregui
Natalia Guajardo-Jauregui
ARAlejandra B. Rodriguez-Romero
Alejandra B. Rodriguez-Romero
AGAndrea C. Garza-Acosta
Andrea C. Garza-Acosta

7 April 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
GGGuillermo Arturo Guaracha-Basañez
Guillermo Arturo Guaracha-Basañez
ICIrazú Contreras-Yáñez
Irazú Contreras-Yáñez
EÁEverardo Álvarez-Hernández
Everardo Álvarez-Hernández
GRGreta Reyes-Cordero
Greta Reyes-Cordero
DFDiana Elsa Flores-Alvarado
Diana Elsa Flores-Alvarado
VPVirginia Pascual-Ramos
Virginia Pascual-Ramos
COVID-19 vaccination is recommended in patients with rheumatic diseases (RDs) to prevent hospitalized COVID-19 and worse outcomes. However, patients’ willingness to receive a SARS-CoV-2 vaccine and the associated factors vary across populations, vaccines, and time. The objective was to identify factors associated with COVID-19 vaccine acceptance (VA) in Mexican outpatients with RDs. This multicenter study was performed between March 1 and September 30, 2021, and four national centers contributed with patients. Participants filled out a questionnaire, which included 32 items related to patients’ perception of the patient-doctor relationship, the COVID-19 vaccine component, the pandemic severity, the RD-related disability, comorbid conditions control, immunosuppressive treatment impact on the immune system, and moral/civil position of COVID-19 vaccine. Sociodemographic, disease-related, and treatment-related variables and previous influenza record vaccination were also obtained. Multiple logistic regression analyses identified factors associated with VA, which was defined based on a questionnaire validated in our population. There were 1439 patients whose data were analyzed, and the most frequent diagnoses were Rheumatoid Arthritis in 577 patients (40.1%) and Systemic Lupus Erythematosus in 427 (29.7%). Patients were primarily middle-aged women (1235 [85.8%]), with (mean±SD) 12.1 (±4.4) years of formal education. Years of education, corticosteroid use, patient perceptions about the vaccine and the pandemic severity, patient civil/moral position regarding COVID-19 vaccine, and previous influenza vaccination were associated with VA. In Mexican patients with RDs, COVID-19 VA is associated with individual social-demographic and disease-related factors, patient´s perceptions, and previous record vaccination. This information is crucial for tailoring effective vaccine messaging in Mexican patients with RDs.

24 November 2020 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
DGDionicio Ángel Galarza-Delgado
Dionicio Ángel Galarza-Delgado
GSGriselda Serna
Griselda Serna
JCJesús Eduardo Compeán-Villegas
Jesús Eduardo Compeán-Villegas
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
RPRita Angélica Pineda-Sic
Rita Angélica Pineda-Sic
DFDiana Elsa Flores-Alvarado
Diana Elsa Flores-Alvarado

1 March 2019 in Reumatología Clínica (English Edition)
Verified
Journal Article
Closed access
VPVirginia Pascual-Ramos
Virginia Pascual-Ramos
DFDiana Elsa Flores-Alvarado
Diana Elsa Flores-Alvarado
MPMargarita Portela-Hernández
Margarita Portela-Hernández
MMMaría del Rocío Maldonado-Velázquez
María del Rocío Maldonado-Velázquez
LALuis Manuel Amezcua-Guerra
Luis Manuel Amezcua-Guerra
CACésar Alejandro Arce-Salinas
César Alejandro Arce-Salinas

2 May 2023 in Rheumatology International
Verified
Journal Article
Open access
PDF file
AGAlfonso Gastelum-Strozzi
Alfonso Gastelum-Strozzi
DFDiana Elsa Flores-Alvarado
Diana Elsa Flores-Alvarado
VPVirginia Pascual-Ramos
Virginia Pascual-Ramos
EÁEverardo Álvarez-Hernández
Everardo Álvarez-Hernández
CPCésar Pacheco-Tena
César Pacheco-Tena
GRGreta Cristina Reyes-Cordero
Greta Cristina Reyes-Cordero
The attitudes toward emerging COVID-19 vaccines have been of great interest worldwide, especially among vulnerable populations such as patients with rheumatic and musculoskeletal diseases (RMDs). The aim of this study was to analyze the relationship between the nationwide number of COVID-19 cases and deaths, and vaccine acceptance or hesitancy of patients with RMDs from four patient care centers in Mexico. Furthermore, we explored differences in acceptance according to specific diagnoses: rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This ecological study was a secondary analysis of a cross-sectional study using a validated questionnaire to measure vaccine acceptance. We generated a global Likert scale to evaluate overall attitudes toward the COVID-19 vaccine. We analyzed data from 1336 patients from March to September 2021: 85.13% (1169) were women, with a mean age of 47.87 (SD 14.14) years. The most frequent diagnoses were RA (42.85%, 559) and SLE (27.08%, 393). 635(47.52%) patients were unvaccinated, 253(18.93%) had one dose and 478(35.77%) had two doses. Of all participating patients, 94% were accepting toward the COVID-19 vaccine. Vaccine acceptance remained consistently high throughout the study. However, differences in vaccine acceptance are identified when comparing diagnoses. The peak of the national epidemic curve coincided with an increase in hesitancy among patients with RA. Contrastingly, patients with SLE became more accepting as the epidemic curve peaked. Mexican patients show high acceptance of the COVID-19 vaccine, influenced in part by a patient’s specific diagnosis. Furthermore, vaccine acceptance increased mirroring the curve of COVID-19 cases and deaths in the country. This should be taken into consideration when updating recommendations for clinical practice.

21 April 2022 in Women & Health
Verified
Journal Article
Closed access
MGMariana Garcia-Leal
Mariana Garcia-Leal
ALAna Laura de Leon-Ibarra
Ana Laura de Leon-Ibarra
PMPablo J. Moreno-Pena
Pablo J. Moreno-Pena
IHIvan Hernandez-Galarza
Ivan Hernandez-Galarza
DGDionicio A. Galarza-Delgado
Dionicio A. Galarza-Delgado
DFDiana E. Flores-Alvarado
Diana E. Flores-Alvarado
To evaluate the current state of the evidence regarding the association of silicone breast implantation with the onset of connective tissue diseases, constitutional symptoms, and rheumatic serological profile in adult women. A comprehensive search was carried out using MEDLINE, Embase, Web of Science and Scopus, from inception to September 2, 2020. Cohort studies assessing the clinical and serological profile of women with cosmetic breast implants were included. Meta-analyses were conducted using risk ratios. A total of 10 cohorts with overall moderate quality of evidence were included in this systematic review. Exposure to silicone breast implants was slightly associated with the development of rheumatoid arthritis [RR: 1.35; (95% CI 1.08 to 1.68); P = .008; I2 = 0%]. However, no significant differences were exhibited between the breast implant-exposed population and controls regarding the rest of the outcomes. In adult women, exposure to silicone breast implantation is not associated with the onset of constitutional symptoms and most connective tissue diseases. A marginal association with rheumatoid arthritis was exhibited, but the certainty of this result is jeopardized by the significant amount of self-reported data for this outcome. Further research is required to adequately explore the clinical significance of these results.